Experimenting with cells in culture, researchers at the Johns Hopkins Kimmel Cancer Center have breathed possible new life into two drugs once considered too toxic for human cancer treatment. The drugs, azacitidine (AZA) and decitabine (DAC), are epigenetic-targeted drugs and work to correct cancer-causing alterations that modify DNA.
The researchers said that the drugs also were found to take aim at a small but dangerous subpopulation of self-renewing cells, sometimes referred to as cancer stem cells, which evade most cancer drugs and cause recurrence and spread.
In a report published in the March 20 issue of Cancer Cell, the Johns Hopkins
Historic Hurd Hall on Johns Hopkins’ East Baltimore campus was filled to capacity on Jan. 13 with students, faculty and staff waiting to hear five scientists—all in the early part of their careers—describe their novel ideas on how to cure metastatic cancer.
The five were finalists, chosen from among 44 entrants, in a competition on creative thinking named for John Rangos Sr., chairman of the Rangos Family Foundation, who funded the awards. Each scientist had 10 minutes to present his or her idea and answer questions from a panel of faculty judges, who would select the winners based on the
Johns Hopkins School of Medicine (Photo credit: Wikipedia)
This year marks the 35th annual Young Investigators’ Award program, when School of Medicine trainee researchers are recognized for their stellar accomplishments in the lab. The event will take place from 4 to 6 p.m. on Friday, April 13, in Mountcastle Auditorium in the Preclinical Teaching Building on the East Baltimore campus.
Researchers will celebrate and share their findings, and 13 students and three fellows will receive awards. Each award includes a cash prize and is named for a former member of the Johns Hopkins community.
Each spring students and fellows look forward